Open AccessMD‐354: What is It Good For?
Author(s) -
Dukat Małgorzata,
Glen Richard A.,
Young Shawquia
Publication year - 2007
Publication title -
cns drug reviews
Language(s) - English
Resource type - Journals
eISSN - 1527-3458
pISSN - 1080-563X
DOI - 10.1111/j.1527-3458.2007.00002.x
Subject(s) - agonist , clonidine , pharmacology , partial agonist , receptor , antagonist , analgesic , nociception , alpha (finance) , serotonin , chemistry , medicine , endocrinology , construct validity , nursing , patient satisfaction
MD‐354 ( meta ‐chlorophenylguanidine) has been identified as a member of a novel class of 5‐HT 3 serotonin receptor agonists. MD‐354 is a 5‐HT 3 receptor partial agonist that has been shown to behave as an agonist in some assays, and as an antagonist in others. MD‐354 also binds at α‐adrenoceptors (ARs) and displays an affinity for α 2B ‐ARs comparable to its affinity for 5‐HT 3 receptors. Although devoid of antinociceptive actions following systemic administration alone, MD‐354 markedly enhances the antinociceptive actions of clonidine in the mouse tail‐flick assay without potentiating the sedative side effects of clonidine. Although studies with MD‐354 are still in progress, some pharmacological findings are described here. MD‐354‐related agents may represent drug adjuvants for the relief of severe pain.